Form 4: CFO Zygmont Receives Significant REVB Stock Grant

Revelation Biosciences CFO Chester S. Zygmont III was granted 390,614 shares of common stock valued at $1.28 per share.

Summary

• Chester S. Zygmont III, Chief Financial Officer of Revelation Biosciences, Inc. (REVB), received a restricted stock grant.
• The grant consisted of 390,614 shares of common stock.
• The shares were granted at a price of $1.28 per share.
• The grant was made under the company's 2021 Equity Incentive Plan.
• The shares will vest quarterly over one year from the grant date of October 29, 2025.
• Following this transaction, Zygmont beneficially owns 395,645 shares indirectly through The Zygmont Family Trust Dated October 25, 2016, and 5 shares indirectly through Czeslaw Capital Fund, LLC.

Sentiment

Score: 7

Explanation: The grant of restricted stock to a key executive like the CFO is generally a positive signal, indicating management alignment and retention efforts. It's a standard compensation practice, hence not extremely positive, but certainly not negative.

Positives

• CFO Chester S. Zygmont III received a significant restricted stock grant of 390,614 shares, aligning management's interests with shareholders.
• The grant is part of the company's 2021 Equity Incentive Plan, indicating a structured approach to executive compensation and retention.

Future Outlook

The restricted stock grant vests quarterly over one year from the grant date of October 29, 2025, indicating a future commitment and retention strategy for the CFO.

Industry Context

Restricted stock grants are a common form of executive compensation in the biotechnology industry, used to incentivize long-term performance and retain key talent. This grant aligns the CFO's interests with the company's future success, a standard practice for growth-oriented biotech firms.

Comparison to Industry Standards

• The grant of 390,614 shares to a CFO is a substantial equity award, typical for executives in early-stage or growth-phase biotechnology companies like Revelation Biosciences, where equity compensation forms a significant part of the overall package.
• Vesting over one year, quarterly, is a relatively short vesting period compared to typical 3-4 year vesting schedules for similar grants in larger, more established biotech firms, which might suggest a focus on near-term performance or a specific retention strategy.
• Companies such as Moderna (MRNA) or BioNTech (BNTX) often use similar equity incentive plans for their executives, though the scale and vesting terms would vary significantly based on company size, maturity, and market capitalization.

Corporate Governance

Related Party Transactions

• The beneficial ownership of 395,645 shares through The Zygmont Family Trust Dated October 25, 2016, is a related party holding, as the CFO is a trustee.
• The beneficial ownership of 5 shares through Czeslaw Capital Fund, LLC, is a related party holding, as the CFO is the sole manager.

Stakeholder Impact

• Shareholders: The grant aligns the CFO's interests with shareholder value creation, potentially leading to better long-term performance. It also represents dilution, though typically minor for individual grants.
• Employees: May signal the company's commitment to retaining key talent and a structured approach to compensation.

Next Steps

• The granted shares will vest quarterly over one year from October 29, 2025.

Key Dates

Recommendation

This Form 4 filing reports a routine executive compensation event (restricted stock grant) and does not provide sufficient information to change an investment thesis. It indicates standard corporate governance and executive retention practices, which are generally neutral to slightly positive for long-term stability but do not warrant a change in investment recommendation based solely on this filing.

Keywords

Revelation Biosciences, REVB, Chester S. Zygmont III, CFO, Restricted Stock Grant, Insider Transaction, Equity Incentive Plan, Form 4, Biotechnology, Executive Compensation